Carl H. June, M.D., Lustgarten GranteeUniversity of Pennsylvania School of Medicine

We’ve come to the tipping point now where there is acceptance that immunotherapy can provide a long-lasting effect and has a lot of promise.
Area of Research: Pancreatic Cancer

Dr. June helped pioneer breakthroughs in CAR T cell therapy, which involves genetically modifying patients’ immune cells to enhance their anti-cancer activity, for patients with blood cancers such as leukemia and lymphoma. Now, he seeks to extend the success of CAR T cells to patients with pancreatic tumors. To do so, Dr. June is using CAR T cells designed to target mesothelin, a protein commonly overexpressed in pancreatic cancer cells, which may be able to improve immune responses against these normally resistant tumors.

Projects and Grants

Mesothelin-specific chimeric antigen receptor (CAR) T cell therapy for pancreatic cancer.

University of Pennsylvania School of Medicine | Pancreatic Cancer | 2015

Let's spread the word about Immunotherapy! Click to share this page with your community.

*Immunotherapy results may vary from patient to patient.

Top